Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (91-100 of 222) with videos related to

Pageof 23
Sort By:
American Journal of Clinical Dermatology|September 27, 2025
Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 TrialsRobert Bissonnette, Fatima Albreiki, Benjamin D Ehst, et al.
Allergy|January 6, 2025
Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic DermatitisJonathan Bar, Ester Del Duca, Eden David, et al.
Journal of the American Academy of Dermatology|September 21, 2010
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult populationKim A Papp, Yves Poulin, Robert Bissonnette, et al.
Journal of Cutaneous Medicine and Surgery|September 28, 2010
Treatment decision needs of psoriasis patients: cross-sectional surveyJerry Tan, Dawn Stacey, Karen Fung, et al.
Dermatology and Therapy|September 21, 2023
Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding StudyA David Burden, Robert Bissonnette, Alexander A Navarini, et al.
American Journal of Clinical Dermatology|January 6, 2025
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic DermatitisLinda Stein Gold, Robert Bissonnette, Seth Forman, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|September 29, 2020
Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema CouncilJonathan I Silverberg, Emma Guttman-Yassky, Tove Agner, et al.
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Update on alefacept safetyDenise Wexler, Gordon Searles, Ian Landells, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 15, 2022
Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa studyRobert Bissonnette, William Abramovits, Étienne Saint-Cyr Proulx, et al.
The British Journal of Dermatology|February 11, 2026
The Gut Microbiome of Non-Atopic Chronic Hand Eczema (CHE) Subjects is Distinct and Enriched in Immuno-Modulatory Bacteria Species compared to Atopic-CHE and Healthy SubjectsRobert Bissonnette, Youssef Salem, Ana Palijan, et al.
Pageof 23

Showing results (91-100 of 222) with videos related to

Sort By:
Pageof 23
American Journal of Clinical Dermatology|September 27, 2025
Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 TrialsRobert Bissonnette, Fatima Albreiki, Benjamin D Ehst, et al.
Allergy|January 6, 2025
Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic DermatitisJonathan Bar, Ester Del Duca, Eden David, et al.
Journal of the American Academy of Dermatology|September 21, 2010
Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult populationKim A Papp, Yves Poulin, Robert Bissonnette, et al.
Journal of Cutaneous Medicine and Surgery|September 28, 2010
Treatment decision needs of psoriasis patients: cross-sectional surveyJerry Tan, Dawn Stacey, Karen Fung, et al.
Dermatology and Therapy|September 21, 2023
Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding StudyA David Burden, Robert Bissonnette, Alexander A Navarini, et al.
American Journal of Clinical Dermatology|January 6, 2025
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic DermatitisLinda Stein Gold, Robert Bissonnette, Seth Forman, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|September 29, 2020
Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema CouncilJonathan I Silverberg, Emma Guttman-Yassky, Tove Agner, et al.
Journal of Cutaneous Medicine and Surgery|January 8, 2010
Update on alefacept safetyDenise Wexler, Gordon Searles, Ian Landells, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 15, 2022
Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa studyRobert Bissonnette, William Abramovits, Étienne Saint-Cyr Proulx, et al.
The British Journal of Dermatology|February 11, 2026
The Gut Microbiome of Non-Atopic Chronic Hand Eczema (CHE) Subjects is Distinct and Enriched in Immuno-Modulatory Bacteria Species compared to Atopic-CHE and Healthy SubjectsRobert Bissonnette, Youssef Salem, Ana Palijan, et al.
Pageof 23